- Completed
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
Updated: Mar 28, 2022

Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Multiple Locations
ClinicalTrials.gov Identifier: NCT02612779
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Elotuzumab : National Cancer Institute
Elotuzumab : MedlinePlus Drug Information
Pomalidomide : National Cancer Institute
Pomalidomide : MedlinePlus Drug Information
Nivolumab : National Cancer Institute
Nivolumab : MedlinePlus Drug Information